Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: A rational approach for the development of cognition enhancers

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 7-14

  Sarter, Martin ^a   Bruno, John P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

acetylcholine; attention; basal forebrain; benzodiazepine receptor inverse agonist; cognition enhancement; cortex; microdialysis

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; BENZODIAZEPINE RECEPTOR INVERSE STIMULATING AGENT;

AGING; ANIMAL; ATTENTION; BRAIN INJURY; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0031081252     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86039-1     Document Type: Conference Paper

References (100)

1. [1] Bessho, T., Oshima, C., Saito, K., Egawa, M. and Tobe, A., Effects of MKC-231, a novel choline uptake enhancer, on AF64A-induced reduction of high affinity choline uptake and impairment of water maze learning in rats, Jpn. J. Pharmacol., 61 (Suppl.) (1993) 90P.
2. [2] Bird, M. and Luszcz, M., Enhancing memory performance in Alzheimer's disease: acquisition assistance and cue effectiveness, J. Clin. Expl. Neuropsychol., 15 (1993) 921-932.
3. [3] Brioni, J.D., Role of GABA during the multiple consolidation of memory, Drug Dev. Res., 28 (1993) 3-27.
4. [4] Bruno, J.P. and Miller J.A., Inhibition of GABAergic transmission: interactions with other transmitter systems, In M. Sarter, D. Nutt and R. Lister (Eds.), Benzodiazepine receptor inverse agonists, Wiley-Liss, New York, 1995, pp. 41-81.
5. 4 amyloid precursor, Proc. Natl. Acad. Sci. USA, 89 (1992) 10075-10078.
6. [6] Chatellier, G., Lacomblez, L. and Derouesne, C., Tetrahydroaminoacridine in Alzheimer's disease: a review of its safety and its effectiveness, Dementia, 2 (1991) 200-206.
7. [7] Chrobak, J.J. and Napier, T.C., Antagonisms of GABAergic transmission within the septum disrupts working/episodic memory in the rat, Neuroscience, 47 (1992) 833-841.
8. [8] Chrobak, J.J., Stackman, R.W. and Walsh, T.J., Intraseptal administration of muscimol produces dose-dependent memory impairments in the rat, Behav. Neural Biol, 52 (1989) 357-369.
9. [9] Cotzias, G. C., Van Woert, M.H. and Schiffer, L.M., Aromatic amino acids and modification of Parkinsonism, N. Engl. J. Med., 276 (1967) 374-378.
10. [10] Cowan, N., Evolving conceptions of memory storage, selective attention, and their mutual constraints within the human information-processing system, Psychol. Bull., 104 (1988) 163-191.
11. A receptor modulators. J. Pharmacol. Exp. Ther., 273 (1995) 241-247.
12. [12] Decker, M.W. and McGaugh, J.L., The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory, Synapse, 7 (1991) 151-168.
13. [13] DeKosky, S.T., Harbaugh, R.E., Schmitt, F.A., Bakay, R.A.E., Chiu, H.C., Knopman, D.S., Reeder, T.M., Shetter, A.G., Senter, H.J., Markesbery, W.R. and the Intraventricular Bethanol Study Group, Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations, Ann. Neurol., 32 (1992) 625-632.
14. [14] Dobbs, R.J., Dobbs, S.M. and Weller, C., Clinical pharmacology, therapeutics and geriatric medicine: an interaction of importance, Br. J. Pharmacol., 32 (1991) 405-406.
15. [15] Duka, T. and Dorow, R., Human experimental psychopharmacology of benzodiazepine receptor inverse agonists. In M. Sarter, D. Nutt and R. Lister (Eds.), Benzodiazepine Receptor Inverse Agonists, Wiley-Liss, New York, 1995, pp. 243-270.
16. [16] Duka, T., Redemann, B., Mager, T. and Voet, B., Scopolamine as a pharmacological tool to study memory processes: application of a cognition enhancer, Soc. Neurosci. Abstr., 19 (1993) 507.5.
17. [17] Durkin, T.P., GABAergic mediation of indirect transsynaptic control over basal and spatial memory testing-induced activation of septo-hippocampal cholinergic activity in mice, Behav. Brain Res., 50 (1992) 155-165.
18. [18] Fadel, J., Moore, H., Sarter, M. and Bruno, J.P., Modulation of cortical acetylcholine efflux following partial deafferentation with 192 IgG-saporin, Soc. Neurosci. Abstr., 20 (1994) 254.10.
19. [19] Fadel, J., Moore, H., Givens, B., Sarter, M. and Bruno, J.P., Bidirectional trans-synaptic modulation of cortical acetylcholine in intact and 192 IgG-saporin-lesioned rats. Soc. Neurosci. Abs., 21 (1995), 763.2
20. [20] Felder, C.C., Ma, A.I., Briley, E.M. and Axelrod, J., Muscarinic acetylcholine receptor subtypes associated with release of Alzheimer amyloid precursor derivatives activate multiple signal pathways, Ann. NY Acad. Sci., 695 (1993) 15-18.
21. [21] Fibiger, H.C., Cholinergic mechanisms in learning, memory and dementia: review of recent evidence, Trends Neurosci., 14 (1991) 220-223.
22. [22] Francis, P.T., Webster, M.T., Chessell, I.P., Holmes, C., Stratman, G.C., Procter, A.W., Cross, A.J., Green, A.R. and Bowen, D.M., Neurotransmitters and second messengers in aging and Alzheimer's disease. Ann. NY Acad. Sci., 695 (1993) 19-26.
23. [23] Giacobini, E., Therapy of Alzheimer disease: symptomatic or neuroprotective? J. Neural Transm., 43 (1994) 211-217.
24. A receptors by benzodiazepine receptor ligands, In E.A. Barnard and E. Costa (Eds.), Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications, Raven Press, New York, 1989, pp. 47-69.
25. [25] Heckers, S., Ohtake, T., Wiley, R.G., Lappi, D.A., Geula, C. and Mesulam, M.-M., Complete and selective cholinergic denervation of rat neocortex and hippocampus but not amygdala by an immunotoxin against the p75 NGF receptor, J. Neurosci., 14 (1994) 1271-1289.
26. A receptor subunit messenger RNA in non-cholinergic neurons of the rat basal forebrain, Neuroscience, 65 (1995) 1077-1086
27. [27] Hern, R., Bierbrauer, J. and Benkert, O., Visual memory in Alzheimer patients: effects of practice, retention interval and severity of cognitive decline, Dementia, 6 (1995) 117-120.
28. [28] Hodges, H., Thrasher, S. and Gray, J.A., Improved radial maze performance induced by the benzodiazepine antagonist ZK 93426 in lesioned and alcohol-treated rats, Behav. Pharmacol., 1 (1989) 45-55.
29. [29] Holley, L.A., Dudchenko, P. and Sarter, M., Attenuation of muscarinic receptor blockade-induced impairment of spatial delayed alternation performance by the triazole MDL 26,479, Psychopharmacology, 109 (1992) 223-230.
30. [30] Holley, L.A., Miller, J.A., Chmielewski, P., Dudchenko, P. and Sarter, M., Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission, Brain Res., 610 (1993) 181-193.
31. [31] Holley, L.A., Turchi, J., Apple, C. and Sarter, M., Dissociation between the attentional effects of infusions of a benzodiazepine receptor agonist and an inverse agonist into the basal forebrain, Psychopharmacology, 120 (1995) 99-108.
32. [32] Holley, L.A., Wiley, R.G., Lappi, D.A. and Sarter, M., Cortical cholinergic deafferentation following the intracortical infusion of 192 IgG-saporin: a quantitative histochemical study. Brain Res., 663 (1994) 277-286.
33. [33] Howard, M.A. and Simons, D.J., Physiologic effects of nucleus basalis magnocellularis stimulation on rat barrel cortex neurons, Expl. Brain Res., 102 (1994) 21-23.
34. [34] Ingham, C.A., Bolam, J.P. and Smith, A.D., GABA-immunoreactive synaptic boutons in the rat basal forebrain: comparison of neurons that project to the neocortex with pallidosubthalamic neurons, J. Comp. Neurol., 273 (1988) 263-282.
35. [35] Jones, G.M.M., Sahakian, B.J., Levy, R., Warburton, D.M. and Gray, J.A., Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease, Psychopharmacology, 108 (1992) 485-494.
36. [36] Lahiri, D.K., Lewis, S. and Farlow, M.R. (1994) Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines, J. Neurosci. Res., 37 (1994) 777-787.
37. [37] Lehericy, S., Hirsch, E.C., Ververa-Pierot, P., Hersh, L.B., Bakchine, S., Piette, F., Duyckaerts, C., Hauw, J.J., Javoy-Agid, F. and Agid, Y., Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease, J. Comp. Neurol., 330 (1993) 15-31.
38. [38] Lowe, S.L., Francis, P.T., Procter, A.W., Palmer, A.M., Davison, A.N. and Bowen, D.M., Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease, Brain, 111 (1988) 785-799.
39. [39] McCormick, D.A., Cellular mechanisms of cholinergic control of neocortical and thalamic neuronal excitability. In M. Steriade and D. Biesold (Eds.), Brain Cholinergic Systems, Oxford University Press, Oxford, 1990, pp. 236-264.
40. [40] McGaugh, J.L., Drug facilitation in memory and learning. In D.H. Efron, J.O. Cole, J. Levine and J.R. Wittenborn, (Eds.), Psychopharmacology: A Review of Progress, US Government Printing Office, Washington, DC, 1968, pp. 891-904.
41. [41] McGaugh, J.L., Drug facilitation of learning and memory, Annu. Rev. Pharmacol., 13 (1976) 229-241.
42. [42] McGaughy, J., Kaiser, T. and Sarter, M., Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density, Behav. Neurosci., 110 (1996) 247-256.
43. [43] McGaughy, J. and Sarter, M., Behavioral vigilance in rats: task validation, and effects of age, amphetamine, and benzodiazepine receptor ligands, Psychopharmacology, 117 (1995) 340-357.
44. [44] McGaughy, J., Turchi, J. and Sarter, M., Crossmodal divided attention in rats: effects of chloridazepoxide and scopolamine, Psychopharmacology, 115 (1994) 213-220.
45. [45] Mesulam, M.M., Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann. Neurol., 28 (1990) 597-613.
46. [46] Metherate, R. and Weinberger, N.M., Cholinergic modulation of responses to single tones produces tone-specific receptive field alterations in cat auditory cortex, Synapse, 6 (1990) 133-145.
47. A receptor. In M. Sarter, D. Nutt and R. Lister (Eds.), Benzodiazepine Receptor Inverse Agonists, Wiley-Liss, New York, 1994, pp. 25-40.
48. [48] Moore, H., Sarter, M. and Bruno, J.P., Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands, Brain Res., 596 (1992) 17-29.
49. [49] Moore, H., Sarter, M. and Bruno, J.P., Bidirectional modulation of stimulated cortical acetylcholine release by benzodiazepine receptor ligands. Brain Res., 627 (1993) 267-274.
50. [50] Moore, H., Sarter, M. and Bruno, J.P., Bidirectional modulation of cortical acetylcholine efflux by infusion of benzodiazepine receptor ligands into the basal forebrain, Neurosci. Lett., 189 (1995) 31-34.
51. [51] Moore, H., Stuckman, S., Sarter, M. and Bruno, J.P., Stimulation of cortical acetylcholine efflux by FG 7142 measured with repeated microdialysis sampling, Synapse, 21 (1995) 324-331.
52. [52] Muir, J.L., Dunnett, S.B., Robbins, T.W. and Everitt, B.J., Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task, Expl. Brain Res., 89 (1992a) 611-622.
53. [53] Muir, J.L., Everitt, B.J. and Robbins, T.W., AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function, J. Neurosci., 14 (1994) 2313-2326.
54. 3 receptor antagonist, ondansetron, Psychopharmacology, 118 (1995) 82-92.
55. [55] Murai, S., Saito, H., Abe, E., Masuda, Y., Odashima, J. and Itoh, T., MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylene aziridium ion in mice, J. Neural Transm., 98 (1994) 1-13.
56. [56] Nitsch, R.N., Slack, B.E., Wurtman, R.J. and Growdon, J.H., Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science, 258 (1992) 304-307.
57. [57] Nissen, M.J. and Bullemer, P., Attentional requirements of learning: evidence from performance measures, Cogn. Psychol., 19 (1987) 1-32.
58. [58] Palmer. A.M., Francis, P.T., Benton, J.S., Sims, N.R., Mann, D.M.A., Neary, D., Snowdon, J.S. and Bowen, D.M., Presynaptic serotonergic dysfunction in patients with Alzheimer's disease, J. Neurochem., 48 (1987) 8-15.
59. [59] Palmer. A.M., Francis, P.T., Bowen, D.M., Benton, J.S., Neary, D., Mann, D.M.A. and Snowdon, J.S., Catecholaminergic neurons assessed ante-mortem in Alzheimer's disease, Brain Res., 414 (1987) 365-375.
60. [60] Parasuraman, R., Greenwood, P.M., Haxby, J.V. and Gady, Y., Visuospatial attention in dementia of the Alzheimer type, Brain, 115 (1992) 711-733.
61. [61] Parasuraman, R. and Haxby, J.V., Attention and brain function in Alzheimer's disease: a review, Neuropsychology, 1 (1993) 242-272.
62. [62] Perry, E.K., Blessed, G., Tomlinson, B.E., Perry, R.H., Crow, T.J., Cross, A.J., Dockray, G.J., Dimaline, R. and Arregui, A., Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes, Neurobiol. Aging 2 (1981) 251-256.
63. [63] Perry, E.K., Johnson, M., Kerwin, J.M., Piggott, M.A., Court, J.A., Shaw, P.J., Ince, P.G., Brown, A. and Perry, R.H., Convergent cholinergic activities in aging and Alzheimer's disease, Neurobiol. Aging 13 (1992) 393-400.
64. [64] Poirier, J., Apolipoprotein E in animal models of CNS injury and Alzheimer's disease, Trends Neurosci., 17 (1994) 525-530.
65. [65] Posner, M.I., Attention: the mechanisms of consciousness, Proc. Natl. Acad. Sci. USA, 91 (1994) 7389-7403.
66. [66] Reinkainen, K.J., Soininen, H. and Riekkinen, P.J., Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy, J. Neurosci. Res., 27 (1990) 576-586.
67. [67] Ridgon, G.C. and Pirch, J.H., Nucleus basalis involvement in conditioned neuronal responses in the rat frontal cortex, J. Neurosci., 6 (1986) 2535-2542.
68. [68] Robbins, T.W. and Everitt, B.J., Arousal systems and attention. In M.S. Gazzaniga (Ed.), The Cognitive Neurosciences, MIT Press, Cambridge, 1994, pp. 703-720.
69. [69] Sahakian, B.J, Jones, G., Levy, R., Gray, J. and Warburton, D., The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type, Br. J. Psychiatry, 154 (1989) 797-800.
70. [70] Sahakian, B.J., Owen, A.M., Morant, N.J., Eagger, S.A., Boddington, S., Crayton, L., Crockford, H.A., Crooks, M., Hill, K. and Levy, R., Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB, Psychopharmacology, 110 (1993) 395-401.
71. [71] Sarter, M., Taking stock of cognition enhancers, Trends Pharmacol. Sci., 12 (1991) 456-461.
72. [72] Sarter, M., Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? Psychopharmacology, 114 (1994) 539-550.
73. [73] Sarter, M. and Bruno, J.P., Cognitive functions of cortical acetylcholine: lessons from studies on the transsynaptic modulation of activated efflux, Trends Neurosci., 17 (1994) 217-221.
74. [74] Sarter, M., Bruno, J.P. and Dudchenko, P., Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification, Psychopharmacology, 101 (1990) 451-459.
75. [75] Sarter, M., Bruno, J.P. and Dudchenko, P., Cholinergic controversies. Trends Neurosci., 14 (1991) 484.
76. [76] Sarter, M., Bruno, J.P., Givens, B.S., Moore, H., McGaughy, J. and McMahon, K., Neuronal mechanisms of drug effects on cognition: cognitive activity as a necessary intervening variable, Cogn. Brain Res., 3 (1996), 329-343.
77. [77] Sarter, M., Hagan, J. and Dudchenko, P., Behavioral screening for cognition enhancers: from indiscriminate to valid testing. Part. I, Psychopharmacology, 107 (1992) 144-159.
78. [78] Sarter, M., Hagan, J. and Dudchenko, P., Behavioral screening for cognition enhancers: from indiscriminate to valid testing. Part. II, Psychopharmacology, 107 (1992) 461-473.
79. [79] Sarter, M., McGaughy, J., Holley, L.A. and Dudchenko, P., Behavioral facilitation and cognition enhancement. In M. Sarter, D. Nutt and R. Lister (Eds.), Benzodiazepine Receptor Inverse Agonists, Wiley-Liss, New York, 1994, pp. 213-241.
80. [80] Sarter, M. and Schneider, H.H., High density of benzodiazepine binding sites in the substantia innominata of the rat, Pharmacol. Biochem. Behav., 30 (1988) 679-682.
81. [81] Sarter, M. and Steckler, T., Spontaneous exploration of a 6-arm radial tunnel maze by basal forebrain lesioned rats: effects of the benzodiazepine receptor antagonist ZK 93 426, Psychopharmacology, 98 (1989) 193-202.
82. [82] Schneider L.S., Clinical pharmacology of aminoacridines in Alzheimer's disease, Neurology, 43 (1993) S64-S79.
83. [83] Schwarz, R.D., Davis, R.E., Gracon, S., Hoover, T., Moos, W.H. and Pavia, M.R., Next generation tacrine, Neurobiol. Aging, 12 (1991) 185-187.
84. [84] Sieghart, W., Subpopulations of benzodiazepine receptors: implications for the pharmacology of inverse agonists. In M. Sarter, D. Nutt and R. Lister (Eds.), Benzodiazepine Receptor Inverse Agonists, Wiley-Liss, New York, 1995, pp. 1-24.
85. [85] Sillito, A.M. and Murphy, P.C., The cholinergic modulation of cortical function. In E.G. Jones and A. Peters (Eds.), Cerebral cortex, Vol. 6, New York, Plenum Press, 1987, 161-185.
86. [86] Sims, N.R., Bowen, D.M., Allen, S.J., Smith, C.C.T., Neary, D., Thomas, D.J. and Davison, A.N., Presynaptic cholinergic dysfunction in patients with dementia, J. Neurochem., 40 (1983) 503-509.
87. [87] Soininen, H., Kosunen, O., Helisalmi, S., Mannermaa, A., Paljärvi, L., Talasniemi, S., Ryynänen, M. and Riekkinen, P.Sr., A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε 4 allele, Neurosci. Lett., 187 (1995) 79-82.
88. [88] Tremblay, N., Warren, R.A. and Dykes, R.W., Electrophysiological studies of acetylcholine and the role of the basal forebrain in the somatosensory cortex of the cat. II. Cortical neurons excited by somatic stimuli, J. Neurophysiol., 64 (1990) 1212-1222.
89. [89] Turchi, J., Holley, L.A. and Sarter, M., Effects of nicotinergic receptor ligands on behavioral vigilance in rats, Psychopharmacology, 118 (1995) 195-205.
90. [90] Voytko, M.L., Olton, D.S., Richardson, R.T., Gorman, L.K., Tobin, J.R. and Price, D.L., Basal forebrain lesions in monkeys disrupt attention but not learning and memory, J. Neurosci., 14 (1994) 167-186.
91. [91] Wiley, R.G., Neural lesioning with ribosome-inactivating proteins: suicide transport and immunolesioning, Trends Neurosci., 15 (1992) 285-290.
92. [92] Wilson, F.A.W. and Rolls, E.T., Learning and memory is reflected in the responses of reinforcement-related neurons in the primate basal forebrain, J. Neurosci., 10 (1990) 1254-1267.
93. A receptor subunit mRNAs in the rat brain - I. Telencephalon, diencephalon, mesencephalon, J. Neurosci., 12 (1992) 1040-1062.
94. [94] Woolf, N.J., Cholinergic systems in mammalian brain and spinal cord, Progr. Neurobiol., 37 (1991) 475-524.
95. [95] Wurtman R.J., Blusztajn, J.K. and Marie, J.-C., 'Autocannibalism' of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease - a hypothesis. Neurochem. Int., 7 (1985) 369-372.
96. [96] Yesavage, J.A., Degree of dementia and improvement with memory training, Clin. Gerontol., 1 (1982) 77-81.
97. [97] Younkin, S.G., Evidence that Aβ42 is the real culprit in Alzheimer's disease, Ann. Neurol., 37 (1995) 287-288.
98. [98] Zaborszky, L., Cullinan, W.E. and Braun, A., Afferents to basal forebrain cholinergic projection neurons: an update. In T.C. Napier, P.W. Kalivas and I. Hanin (Eds.), The Basal Forebrain, Plenum Press, New York, 1991, pp. 43-100.
99. [99] Zaborszky, I., Heimer, L., Eckenstein, F. and Leranth, C., GABAergic input to cholinergic forebrain neurons: an ultrastructural study using retrograde tracing of HRP and double immunolabeling, J. Comp. Neurol, 250 (1986) 282-295.
100. [100] Zigmond, M.J. and Stricker, E.M., Animal models of Parkinsonism using selective neurotoxins: clinical and basic implications, Int. Rev. Neurobiol., 13 (1989) 1-79.